About this Activity
This program will provide clinicians with a thorough understanding of navigating the clinical conundrum of MDD.

Learning Objectives
By participating in this symposium, learners will be able to:

• Understand the importance of achieving remission in depression and assess treatment considerations
• Identify factors that may predict treatment response
• Describe how the tolerability profiles of antidepressants impact adherence

Who Will Benefit
This activity was designed to meet the continuing education needs of psychiatrists and other physicians. Other mental health professionals may find this activity informative and should check with their state licensing and certification boards to determine if it meets their continuing education requirements.

Your Distinguished Faculty

	Rakesh Jain, MD, MPH Director of Psychiatric Drug Research, R/D Clinical Research, University of Texas, Houston
	James W. Jefferson, MD Distinguished Senior Scientist, Madison Institute of Medicine, Inc.; Director, Healthcare Technology Systems, Inc.; Clinical Professor of Psychiatry, University of Wisconsin

Faculty Disclosures
Rakesh Jain, MD, MPH, is a member of the Speakers Bureau for Jazz, Eli Lilly and Company, Takeda, Pfizer, and Shire Pharmaceuticals Inc. He serves as a consultant for Takeda, Lilly, Impax, and Addrenex. He also receives grants/research support and/or honoraria from GlaxoSmithKline, Eli Lilly and Company, Abbott, Pfizer Inc., Jazz, Merck, Sepracor, Forest, Shire, Addrenex, and Takeda Pharmaceuticals America, Inc.

James W. Jefferson, MD, has received grants and/or research support from Bristol-Myers Squibb Company, Forest, GlaxoSmithKline, Janssen, L.P., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Organon Pharmaceuticals USA, Inc., Pfizer Inc., Roche Laboratories Inc., Solvay Pharmaceuticals, UCB Pharma Inc., and Wyeth Pharmaceuticals Inc. He has also has received honoraria from Abbott, AstraZeneca, Bristol-Myers Squibb Company, Forest, GlaxoSmithKline, Eli Lilly and Company, Pfizer Inc., UCB Pharma Inc., Shire Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has also served as a consultant for GlaxoSmithKline. He is the principal of Healthcare Technology Systems, Inc., and a stockholder in Bristol-Myers Squibb Company, GlaxoSmithKline, and SciClone. He receives other financial or material support from the organizations listed above from time to time.

Commercial Support

Supported by an educational grant from Eli Lilly and Company

Disclaimers
The content of this video activity may include product information that is inconsistent with or outside of the approved labeling for these products in the United States. Before prescribing any medication, you must familiarize yourself with the manufacturer's product information.

To earn continuing education credit, view this online course and complete the posttest and evaluation provided. A passing score of 75% or more must be achieved on the posttest. A link is provided within this online activity to access the posttest and evaluation. You will have the option of printing a CME Certificate for your records after submission of the evaluation.

CME LLC and are not responsible for the speaker's statements, materials, acts or omissions.

Continuing Medical Education
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Content Originally Presented: 10/31/08; 12:30-2:30pm
Online Date: 12/20/08
Credit Expiration Date: 12/20/09

This activity is based on the symposium Navigating the Clinical Conundrum of MDD on October 30, 2008 in San Diego, CA and may not reflect the most current data. Participants who attended the live symposium mentioned above cannot claim credit for this activity.